COMMUNIQUÉS West-GlobeNewswire

Statement re Grant of Options and Warrants
29/04/2025
DXS INTERNATIONAL PLC (AQSE: DXSP) Granting of Share Options and Warrants The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of [...]
The Board of Directors of Financière de Tubize appoints Bruno Holthof as new Chair
29/04/2025
The Board of Directors of Financière de Tubize appoints Bruno Holthof as new Chair As Gaëtan Hannecart did not seek renewal of his director’s mandate at the general shareholders meeting held on April 25, 2025, the Board [...]
Le Conseil d'Administration de la Financière de Tubize nomme Bruno Holthof comme Président
29/04/2025
Le Conseil d'Administration de la Financière de Tubize nomme Bruno Holthof comme Président Suite à la décision de Gaëtan Hannecart de ne pas solliciter le renouvellement de son mandat d'administrateur lors de l' [...]
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update
29/04/2025
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Successful strategic shift towards a focus on inflammatory and fibrotic diseases, in particular on kidney disease [...]
Santhera Publishes Agenda for its Annual General Meeting
29/04/2025
Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, [...]
New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine
29/04/2025
Daridorexant improved sleep maintenance throughout the entire night, including the last quarter, while also improving next-morning sleepiness. Daridorexant improved next-morning sleepiness compared to placebo from as [...]
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
29/04/2025
Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc 1 , +12% USD) with core operating income 1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto (+22% cc), Kisqali [...]
Santhera Full Year Results for the Year Ended 31 December 2024
29/04/2025
Transformational year following the successful launch of AGAMREE® Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces its full year results for the year ended 31 December 2024. [...]
Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer
29/04/2025
The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis [...]
Lumineye Introduces Sublingual Nano-Drop Formula to Help Support Normal Eye Comfort and Clarity
29/04/2025
Sheridan, Wyoming, USA, April 29, 2025 (GLOBE NEWSWIRE) -- Lumineye , a pioneering company in the health and wellness sector, today announced the launch of its new product: The Lumineye Nanodrop. This advanced dietary [...]
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
29/04/2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of [...]
UK Company, Stablepharma Ltd, enters Phase 1 Clinical Trials with world-first Fridge-Free Tetanus & Diphtheria Vaccine
29/04/2025
LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first [...]
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
29/04/2025
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the [...]
ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
28/04/2025
– Oral and poster presentations will highlight advancements from ElevateBio’s two business units: Life Edit, its gene editing and R&D technology business, and BaseCamp ® , its process development and cGMP [...]
ARCPOINT REPORTS 2024 YEAR END FINANCIAL RESULTS AND ANNOUNCES MANAGEMENT CHANGE
28/04/2025
Greenville, South Carolina, April 28, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) is pleased to report that it has filed its 2024 year end, audited Financial Statements and [...]
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
28/04/2025
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies [...]
Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025
28/04/2025
NEW YORK, 28 avr. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour [...]
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
28/04/2025
Reflects business philosophy of commercial success through patient accessibility Recently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and [...]
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
28/04/2025
Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK ® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster [...]

Pages